Abstract
There have been a number of highly publicized safety-based drug withdrawals in the United States in recent years. We conducted a review of drugs withdrawn since 1993 and examined trends in drug withdrawals. Our objective was to determine the frequency and characteristics of withdrawn drugs and trends since 1993, and to discuss the implications of the findings. We found that a mean of 1.5 drugs per year have been withdrawn since 1993, and that the number of withdrawals has not increased over time. However, some recent drug withdrawals have impacted large numbers of people. The rate of withdrawals alone is not an adequate measure of the status of drug safety in the US, and there is a serious dearth of data that can be used to examine the impact of drug withdrawals. Although drug withdrawals are an important issue to address, drug safety policies need to be developed within the broader context of drug safety and effectiveness. A comprehensive approach will be needed to address the improvement of drug safety. We propose improvements to the evidence base to increase drug safety and assess how new scientific evidence can be incorporated into drug safety efforts.
Keywords: Prescription drug withdrawals, drug safety, evidence base, policy implications, pharmacoepidemiology, drug surveillance
Current Drug Safety
Title: Drug Withdrawals in the United States: A Systematic Review of the Evidence and Analysis of Trends
Volume: 2 Issue: 3
Author(s): Amalia M. Issa, Kathryn A. Phillips, Stephanie Van Bebber, Hima G. Nidamarthy, Karen E. Lasser, Jennifer S. Haas, Brian K. Alldredge, Robert M. Wachter and David W. Bates
Affiliation:
Keywords: Prescription drug withdrawals, drug safety, evidence base, policy implications, pharmacoepidemiology, drug surveillance
Abstract: There have been a number of highly publicized safety-based drug withdrawals in the United States in recent years. We conducted a review of drugs withdrawn since 1993 and examined trends in drug withdrawals. Our objective was to determine the frequency and characteristics of withdrawn drugs and trends since 1993, and to discuss the implications of the findings. We found that a mean of 1.5 drugs per year have been withdrawn since 1993, and that the number of withdrawals has not increased over time. However, some recent drug withdrawals have impacted large numbers of people. The rate of withdrawals alone is not an adequate measure of the status of drug safety in the US, and there is a serious dearth of data that can be used to examine the impact of drug withdrawals. Although drug withdrawals are an important issue to address, drug safety policies need to be developed within the broader context of drug safety and effectiveness. A comprehensive approach will be needed to address the improvement of drug safety. We propose improvements to the evidence base to increase drug safety and assess how new scientific evidence can be incorporated into drug safety efforts.
Export Options
About this article
Cite this article as:
Issa M. Amalia, Phillips A. Kathryn, Van Bebber Stephanie, Nidamarthy G. Hima, Lasser E. Karen, Haas S. Jennifer, Alldredge K. Brian, Wachter M. Robert and Bates W. David, Drug Withdrawals in the United States: A Systematic Review of the Evidence and Analysis of Trends, Current Drug Safety 2007; 2 (3) . https://dx.doi.org/10.2174/157488607781668855
DOI https://dx.doi.org/10.2174/157488607781668855 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents Therapeutic Agents for Cancer
Recent Patents on Anti-Cancer Drug Discovery Aging and Remodeling During Healing of the Wounded Heart: Current Therapies and Novel Drug Targets
Current Drug Targets Homocysteine and Heart Failure: An Overview
Recent Patents on Cardiovascular Drug Discovery Benzopyran Derivatives as Cardio-selective ATP-sensitive Potassium Channel Openers: A Review
Mini-Reviews in Medicinal Chemistry Secondary Stroke Prevention in Patients with Cryptogenic Stroke and Patent Foramen Ovale
Vascular Disease Prevention (Discontinued) Editorial [Hot Topic: The Adenosinergic System - From Physiology to Pathology and Therapeutics (Guest Editors: A. Rees and J. Ham)]
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Cannabinoid Receptor Type 2 Activation in Atherosclerosis and Acute Cardiovascular Diseases
Current Medicinal Chemistry Strict Adherence to Guidelines in Decision Making for Coronary Angiography in Patients Who have Survived a Q Wave Myocardial Infarction; 2-Year Outcome in a Greek Population
Vascular Disease Prevention (Discontinued) Combination of Phytosterols and Omega-3 Fatty Acids: A Potential Strategy to Promote Cardiovascular Health
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Bleeding, Vertebral Fractures and Vascular Calcifications in Patients Treated with Warfarin: Hope for Lower Risks with Alternative Therapies
Current Vascular Pharmacology A Comparative Literature Review Exploring Hypertension Drugs that Lower Target Organ Damage Above and Beyond Reducing Blood Pressure Based on Research Studies Between 1992 and 2006
Current Hypertension Reviews Opioids: Old Drugs for Potential New Applications
Current Pharmaceutical Design Fibrate-Associated Adverse Effects Beyond Muscle and Liver Toxicity
Current Pharmaceutical Design Selective Serotonin Reuptake Inhibitors (SSRIs): Therapeutic Drug Monitoring and Pharmacological Interactions
Current Medicinal Chemistry Blood Pressure Measurement: Lessons Learned from Our Ancestors
Current Pharmaceutical Design The Therapeutic Role of Taurine in Ischaemia-Reperfusion Injury
Current Pharmaceutical Design Diabetic Cardiovascular Disease – AMP-Activated Protein Kinase (AMPK) as a Therapeutic Target
Cardiovascular & Hematological Agents in Medicinal Chemistry Cardiac MRI in Infiltrative Disorders: A Concise Review
Current Cardiology Reviews Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial
Current Vascular Pharmacology Role of Molecular Analysis After Autopsy Negative Sudden Death in the Young
Current Pediatric Reviews